Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
RESEARCH TOOLSreports
Holding MDGL?
Track your performance easily
MDGL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$168.25 - $368.29
Previous Close$314.17
Volume326.80K
Average Volume (3M)376.36K
Market Cap
$6.85B
Enterprise Value$5.97B
Total Cash (Recent Filing)$998.63M
Total Debt (Recent Filing)$119.14M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Feb 26, 2025EPS Estimate
-$4.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.07
Shares Outstanding21,810,407
10 Day Avg. Volume513,369
30 Day Avg. Volume376,361
Standard Deviation0.44
R-Squared0.00305
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)8.82
Price to Sales (P/S)81.94
Price to Cash Flow (P/CF)-24.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue77.76
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-15.20
Forecast
1Y Price Target
$377.45Price Target Upside19.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Madrigal Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMDGL announced that enrollment in the Phase 3 MAESTRO-NASH OUTCOMES trial of Rezdiffra has completed, exceeding the company’s initial enrollment target by ~20%.
Financial PerformanceNet revenues significantly exceeded expectations, boosting investor confidence in MDGL's launch execution and demand for NASH therapeutics.
Market AdoptionMDGL achieved coverage for more than 80% of commercial lives, showing substantial improvement from previous quarters.
Bears Say
Competitive PressureAnticipated competitive pressure from GLP-1-based therapies could impact future market penetration and share for Rezdiffra due to uncertainties in payer coverage policy.
Regulatory RisksFailure to obtain FDA or EMA approvals poses a significant risk to the stock's rating and price target.
Reimbursement ChallengesThe reimbursement process is complicated, requiring proof of diagnosis and taking an average of three weeks from prescription to first dose, which could hinder patient access.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MDGL FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $168.25 and its highest was $368.29 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Feb 26, 2025 which is in 97 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Oct 31, 2024. The company reported -$4.92 earnings per share for the quarter, beating the consensus estimate of -$6.748 by $1.828.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -$4.51.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 21,810,408 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$4.92 in its last earnings report, beating expectations of -$6.748. Following the earnings report the stock price went up 20.104%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Among the largest hedge funds holding Madrigal Pharmaceuticals Inc’s share is Baker Bros Advisors LP. It holds Madrigal Pharmaceuticals Inc’s shares valued at 419M.
---
Madrigal Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$377.45 (19.04% Upside)
$377.45 (19.04% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 92%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.83%
12-Months-Change
Fundamentals
Return on Equity
-129.76%
Trailing 12-Months
Asset Growth
351.02%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
---
MDGL Earnings Call
Q3 2024
0:00 / 0:00
---
MDGL Stock 12 Month Forecast
Average Price Target
$377.45
▲(19.04% Upside)
Technical Analysis
Viking Therapeutics
―
Akero Therapeutics
―
Galectin Therapeutics
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering MDGL
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+36.47%
assigned a buy rating yesterday
Copying Ritu Baral's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +36.47% per trade.
---